Jan Jacques Michiels

Summary

Affiliation: The Hague
Country: The Netherlands

Publications

  1. ncbi WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders
    Jan Jacques Michiels
    Department of Hematology, University Hospital, Antwerp, Belgium
    Leuk Res 31:1031-8. 2007
  2. doi Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:154-66. 2009
  3. ncbi Non-invasive diagnosis of pulmonary embolism, anno 2005
    J J Michiels
    Goodheart Institute and Foundation, Hemostasis Thrombosis and Vascular Research, Goodheart Institute, Rotterdam, The Netherlands
    Acta Chir Belg 105:26-34. 2005
  4. ncbi Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 31:577-601. 2005
  5. doi Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:111-8. 2009
  6. ncbi Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications
    Jan J Michiels
    Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 32:174-207. 2006
  7. ncbi The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders
    Jan J Michiels
    Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
    Semin Thromb Hemost 32:307-40. 2006
  8. ncbi Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF)
    J J Michiels
    Department of Hematology, University Hospital Antwerp Wilrijkstraat 10, 2650 Edegem Antwerp, Belgium
    Pathol Biol (Paris) 55:92-104. 2007
  9. ncbi Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications
    Jan J Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 32:577-88. 2006
  10. ncbi Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3
    Jan J Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
    Semin Thromb Hemost 32:636-45. 2006

Detail Information

Publications43

  1. ncbi WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders
    Jan Jacques Michiels
    Department of Hematology, University Hospital, Antwerp, Belgium
    Leuk Res 31:1031-8. 2007
    ..The proposed WHO/ECMP criteria allow a cross talk between clinicians, pathologists and scientists to much better characterize the nature and natural history of each of the WHO/CMP defined early and overt MPDs...
  2. doi Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:154-66. 2009
    ....
  3. ncbi Non-invasive diagnosis of pulmonary embolism, anno 2005
    J J Michiels
    Goodheart Institute and Foundation, Hemostasis Thrombosis and Vascular Research, Goodheart Institute, Rotterdam, The Netherlands
    Acta Chir Belg 105:26-34. 2005
    ..The combination of clinical assessment, a rapid ELISA VIDAS D-dimer followed by CUS will reduce the need for helical spiral CT by 40 to 50%...
  4. ncbi Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 31:577-601. 2005
    ..Proper recommendations of FVIII/vWF concentrates using FVIII:C and vWF:RCo unit dosing for the prophylaxis and treatment of bleeding episodes in type 2 disease that is nonresponsive to DDAVP and in type 3 vWD are proposed...
  5. doi Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:111-8. 2009
    ..Carriers of a heterozygous missense mutation in the VWFpp region (D1-D2 domain) of the VWF gene may present mild VWD type 1 and show a typical multimeric pattern with a heavy predominance of VWF dimers...
  6. ncbi Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications
    Jan J Michiels
    Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 32:174-207. 2006
    ....
  7. ncbi The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders
    Jan J Michiels
    Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
    Semin Thromb Hemost 32:307-40. 2006
    ....
  8. ncbi Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF)
    J J Michiels
    Department of Hematology, University Hospital Antwerp Wilrijkstraat 10, 2650 Edegem Antwerp, Belgium
    Pathol Biol (Paris) 55:92-104. 2007
    ....
  9. ncbi Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications
    Jan J Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 32:577-88. 2006
    ..AvWS associated with IgG BMG does not respond to corticosteroids, immune suppression, or chemotherapy. AvWS associated with IgM BMG is rare and does not respond to any conventional treatment...
  10. ncbi Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3
    Jan J Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
    Semin Thromb Hemost 32:636-45. 2006
    ..Such guidelines should be stratified for the severity of bleeding, the type of surgery (either minor or major), and also for the severity and type of vWD (i.e., either type 2 or 3 vWD)...
  11. ncbi Different accuracies of rapid enzyme-linked immunosorbent, turbidimetric, and agglutination D-dimer assays for thrombosis exclusion: impact on diagnostic work-ups of outpatients with suspected deep vein thrombosis and pulmonary embolism
    Jan J Michiels
    Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Semin Thromb Hemost 32:678-93. 2006
    ..The combined strategy of a rapid ELISA VIDAS D-dimer followed by objective testing with CUS for DVT and by spiral CT for PE will reduce the need for noninvasive imaging techniques by 40 to 50%...
  12. doi Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:167-76. 2009
    ..Such guidelines should be stratified for the severity of bleeding, the type of surgery (minor or major) and also for the bleeding score in either VWD type 1, 2 or 3...
  13. doi Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:85-97. 2009
    ....
  14. doi Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:119-27. 2009
    ....
  15. ncbi Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
    Ann Hematol 83:504-12. 2004
    ..These observations indicate that both Ph+ ET and Ph+ thrombocythemia associated with CML can be regarded as early manifestations of the chronic stable phase of CML...
  16. ncbi Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera
    Jan Jacques Michiels
    Department of Haematology, Haemostasis Thrombosis Research, University Hospital Antwerp, Antwerp, Belgium
    Platelets 15:67-84. 2004
    ..The microvascular syndrome associated with thrombocythaemia in PV patients in remission after bloodletting is best controlled by low-dose aspirin (50-100 mg/day) or by reduction of platelet count to normal (< 350 x 10(9)/l)...
  17. ncbi Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis
    J J Michiels
    Department of Clinical Hematology, Academic Medical Center, Amsterdam, The Netherlands
    Neth J Med 54:46-62. 1999
    ....
  18. ncbi Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG
    J J Michiels
    Goodheart Institute, Rotterdam, The Netherlands
    Leuk Lymphoma 36:239-53. 2000
    ....
  19. ncbi Strategies for the safe and effective exclusion and diagnosis of deep vein thrombosis by the sequential use of clinical score, D-dimer testing, and compression ultrasonography
    J J Michiels
    Clinical Hemostasis and Thrombosis, Department of Hematology, University Hospital Antwerp and the Goodheart Institute Center for Hemostasis, Thrombosis, and Vascular Pathology, Rotterdam, The Netherlands
    Semin Thromb Hemost 26:657-67. 2000
    ....
  20. ncbi Atypical variant of acquired von Willebrand syndrome in Wilms tumor: is hyaluronic acid secreted by nephroblastoma cells the cause?
    J Michiels
    Clinical Hemostasis and Thrombosis, Department of Hematology, University Hospital Antwerp, Belgium
    Clin Appl Thromb Hemost 7:102-5. 2001
    ..The causative agent is thought to be hyaluronic acid secreted by nephroblastoma cells of the Wilms tumor. Prospective studies to determine the nature of AvWS in children with Wilms tumor are warranted...
  21. ncbi Acquired von Willebrand syndrome in systemic lupus erythematodes
    J J Michiels
    Clinical Hemostasis and Thrombosis, Department of Hematology, University Hospital Antwerp, Edegem, Belgium
    Clin Appl Thromb Hemost 7:106-12. 2001
    ..All reported cases of AvWS in SLE were cured by appropriate treatment of the underlying autoimmune disease with prednisone or immunosuppression...
  22. ncbi Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine
    J J Michiels
    Clinical Hemostasis and Thrombosis, Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
    Clin Appl Thromb Hemost 7:113-5. 2001
    ..The complete relief of AvWS via treatment of hypothyroidism with thyroxine is the final proof of this association and causal relationship...
  23. ncbi Exclusion and diagnosis of deep vein thrombosis in outpatients by sequential noninvasive tools
    J J Michiels
    Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Int Angiol 21:9-19. 2002
    ..The rapid ELISA D-dimer first followed by risk-based no, single or repeated CUS will be the most cost-effective strategy...
  24. ncbi Bilateral adrenal swelling as a cause of chest, back, and upper abdominal pain in essential thrombocythemia and polycythemia vera is due to microvascular ischemic thrombosis rather than to hemorrhage
    J J Michiels
    Goodheart Institute Rotterdam, Hemostasis, Thrombosis and Vascular Research and MPD Center Europe, Erasmus Tower, Veenmos 13, Netherlands
    Ann Hematol 81:691-4. 2002
    ....
  25. ncbi Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia
    J J Michiels
    Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, The Netherlands
    Ann Hematol 82:153-9. 2003
    ....
  26. ncbi Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts
    J J Michiels
    Hemostasis, Thrombosis and Vascular Research, Department of Hematology, University Hospital, Antwerp, Belgium
    Pathol Biol (Paris) 51:167-75. 2003
    ....
  27. ncbi Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia
    Jan Jacques Michiels
    Goodheart Institute, MPD Center Europe, Rotterdam, The Netherlands
    Hematol J 5:93-102. 2004
    ....
  28. ncbi Non-invasive exclusion and diagnosis of pulmonary embolism by sequential use of the rapid ELISA D-dimer assay, clinical score and spiral CT
    J J Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital, Antwerp, Belgium
    Int Angiol 22:1-14. 2003
    ..Therefore, a helical spiral CT can replace both the VP-scan and pulmonary angiography to safely rule in and out PE. A negative rapid ELISA VIDAS D-dimer test result will reduce the need for helical spiral CT by 25% to 35%...
  29. doi Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene
    Alain Gadisseur
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:145-53. 2009
    ..The laboratory manifestations and molecular defects in the A1 domain causing VWD type 2M and 2U are clearly distinct from all variants of type 1 VWD and also from all other variants [VWD type 2A, 2B, 2E (IIE) and 2C (IIC)]...
  30. doi Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Wil
    Alain Gadisseur
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:128-38. 2009
    ....
  31. doi Laboratory diagnosis and molecular classification of von Willebrand disease
    Alain Gadisseur
    Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
    Acta Haematol 121:71-84. 2009
    ..2 to 4.69 indicating clearance of the VWF/FVIII complex. Normal VWFpp/Ag ratios in mild VWD type 1 with mutations in the D1-D2 and the D4-B-C domains reflect a synthesis/secretion defect...
  32. ncbi Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thromboph
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Hemostasis Thrombosis Research, Antwerp, Belgium
    Platelets 17:528-44. 2006
    ....
  33. ncbi Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD
    Jan Jacques Michiels
    Department of Hematology, Hemostasis and Thrombosis Research, University Hospital Antwerp
    Clin Appl Thromb Hemost 12:277-95. 2006
    ..A DDAVP challenge test clearly differentiates between dominant type 1 VWD phenotype and dominant type 2 M VWD...
  34. ncbi Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Clin Appl Thromb Hemost 12:397-420. 2006
    ..2E appears to be less well defined, is usually autosomal dominant, and accounts for about one third of patients with 2A in a large cohort of VWD patients...
  35. ncbi Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P)
    Jan Jacques Michiels
    Haemostasis and Thrombosis Research, Department of Haematology, Antwerp University Hospital, University of Antwerp, Belgium
    Blood Coagul Fibrinolysis 15:323-30. 2004
    ....
  36. ncbi Screening for deep vein thrombosis and pulmonary embolism in outpatients with suspected DVT or PE by the sequential use of clinical score: a sensitive quantitative D-dimer test and noninvasive diagnostic tools
    Jan Jacques Michiels
    Hemostasis and Thrombosis Research, Department of Hematology, University Hospital Antwerp, Antwerp, Belgium
    Semin Vasc Med 5:351-64. 2005
    ..The combination of clinical assessment, a rapid ELISA VIDAS D-dimer, followed by CUS will reduce the need for helical spiral CT by 40 to 50%...
  37. ncbi Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3
    Jan Jacques Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Clin Appl Thromb Hemost 13:14-34. 2007
    ....
  38. ncbi Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin
    Jan Jacques Michiels
    Hemostasis Thrombosis Research, Department of Hematology, University Hospital Antwerp, Belgium
    Blood Cells Mol Dis 36:199-205. 2006
    ..000/microl)...
  39. ncbi Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia)
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, University of Antwerp, Belgium
    Int J Hematol 76:133-45. 2002
    ..On the other hand, survival is substantially shortened in IMF/AMM, even for patients with thrombocythemia as a frequent finding of prefibrotic and early stage IMF/AMM...
  40. ncbi Preface: platelets in inflammation and atherothrombosis
    Jan Jacques Michiels
    Bloodcoagulation Research in Vascular Medicine, University Hospital Antwerp, Faculty of Medicine, Antwerp University, Goodheart Institute, Hemostasis Thrombosis Research and Science Center, Erasmus Tower, Rotterdam, The Netherlands
    Semin Thromb Hemost 33:119-22. 2007
  41. ncbi Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond
    Jan Jacques Michiels
    Department of Hematology, University Hospital Antwerp, Belgium
    Hematology 10:215-23. 2005
    ....
  42. ncbi Fibrin D-dimer testing for venous and arterial thrombotic disease
    Jan Jacques Michiels
    Goodheart Institute and Foundation, Hematology Hemostasis Thrombosis Science Center, Rotterdam, The Netherlands
    Semin Vasc Med 5:311-4. 2005
  43. ncbi Obesity, health issues, and cardiovascular disease
    Luc F Van Gaal
    Department of Diabetology, Metabolism and Clinical Nutrition, Faculty of Medicine, Antwerp University Hospital, Antwerp, Belgium
    Semin Vasc Med 5:1-2. 2005